Global BulletinAll NewsFDA Approval AlertWomen in Oncology
Expert InterviewsAround the PracticeBetween the LinesFace OffFrom All AnglesMeeting of the MindsOncViewPodcastsTraining AcademyTreatment Algorithms with the Oncology BrothersVideos
Conferences
All JournalsEditorial BoardFor AuthorsYear in Review
Frontline ForumSatellite Sessions
CME/CE
Awareness MonthInteractive ToolsNurse Practitioners/Physician's AssistantsPartnersSponsoredSponsored Media
Career CenterSubscribe
Adverse Effects
Brain Cancer
Breast CancerBreast CancerBreast Cancer
Gastrointestinal CancerGastrointestinal CancerGastrointestinal CancerGastrointestinal CancerGastrointestinal CancerGastrointestinal Cancer
Genitourinary CancersGenitourinary CancersGenitourinary CancersGenitourinary Cancers
Gynecologic CancersGynecologic CancersGynecologic CancersGynecologic Cancers
Head & Neck Cancer
Hematologic OncologyHematologic OncologyHematologic OncologyHematologic Oncology
InfectionInfection
Leukemia
Lung CancerLung CancerLung Cancer
Lymphoma
Neuroendocrine Tumors
Oncology
Pediatric Cancers
Radiation Oncology
Sarcoma
Screening
Skin Cancer & Melanoma
Surgery
Thyroid Cancer
Spotlight -
  • Radiation Oncology
  • Surgery
Adverse Effects
Brain Cancer
Breast CancerBreast CancerBreast Cancer
Gastrointestinal CancerGastrointestinal CancerGastrointestinal CancerGastrointestinal CancerGastrointestinal CancerGastrointestinal Cancer
Genitourinary CancersGenitourinary CancersGenitourinary CancersGenitourinary Cancers
Gynecologic CancersGynecologic CancersGynecologic CancersGynecologic Cancers
Head & Neck Cancer
Hematologic OncologyHematologic OncologyHematologic OncologyHematologic Oncology
InfectionInfection
Leukemia
Lung CancerLung CancerLung Cancer
Lymphoma
Neuroendocrine Tumors
Oncology
Pediatric Cancers
Radiation Oncology
Sarcoma
Screening
Skin Cancer & Melanoma
Surgery
Thyroid Cancer
    • Conferences
    • CME/CE
    • Career Center
    • Subscribe
Advertisement

Study Links Smoking in College to Other Risky Student Behaviors

March 1, 1998
Publication
Article
OncologyONCOLOGY Vol 12 No 3
Volume 12
Issue 3

College students who smoke not only are endangering their health but also are likely to have adopted other risky behaviors. A new study by researchers at Dana-Farber Cancer Institute and the Harvard School of Public Health has found that college students who smoke are more likely to use marijuana and other illegal drugs, to be sexually promiscuous, and to be uninvolved in sports and athletic activities.

College students who smoke not only are endangering their health but also are likely to have adopted other risky behaviors. A new study by researchers at Dana-Farber Cancer Institute and the Harvard School of Public Health has found that college students who smoke are more likely to use marijuana and other illegal drugs, to be sexually promiscuous, and to be uninvolved in sports and athletic activities.

The study, published in the January issue of the American Journal of Public Health, suggests that encouraging students to participate in more productive aspects of campus life might have the additional benefit of deterring them from smoking.

“College presents an opportunity to reach smokers while society still has ‘institutional’ access to them,” says study coauthor Karen Emmons, PhD, of Dana-Farber and the Harvard School of Public Health. “Smoking should serve as a warning sign to resident assistants and other college counselors that these students need to be drawn more fully into college life.”

Large Number of Students Surveyed
The study is based on a survey of more than 17,000 students at 140 four-year colleges across the country. Students were asked to complete a questionnaire about their use of alcohol, cigarettes, and illicit drugs and to provide information on their living arrangements, lifestyle, and academic performance.

Analysis of the survey showed that 22% of the students had smoked within the previous 30 days and 25% were former smokers—meaning that almost half of all students surveyed had smoked at some point in their lifetime. Among the current smokers, 34% smoked at least half a pack a day and 14% smoked a pack or more a day. College smoking was found to be linked with a variety of behaviors that are either physically or psychologically unhealthy. Students who engaged in binge-drinking prior to college, for example, were almost twice as likely to smoke in college than students who did not binge-drink. Students who smoked were also more likely to use marijuana and to have had multiple sex partners during the previous month.

Lifestyle Choices Influence Smoking
Lifestyle choices were shown to exert a powerful influence on student smoking. Researchers found that smokers were less likely to participate in intercollegiate athletics (a trend that held for male students only) and tended to be less involved in community service, religion, arts, and productive activities and to be more involved in leisure activities. Membership in a fraternity or sorority also increased the likelihood of being a smoker, as did frequent attendance at parties.

One intriguing finding of the study was that risk-taking behavior was an even more powerful predictor of smoking in female students than in their male counterparts.

“Clearly, there is a strong association between students’ lifestyle and the decision of whether or not to smoke,” Emmons says. “The link between high school binge drinking and college smoking may indicate that smoking among college students is part of a risk-taking lifestyle initiated well before college.”

Encouraging Healthy Lifestyles
Fortunately, colleges and universities have at their disposal a variety of options for encouraging healthy lifestyles among students, Emmons notes, from policies banning smoking in university buildings to programs encouraging involvement in the arts, sports, and community service. “By instituting strong policies regarding smoking, universities can establish norms about what values and activities they consider acceptable and what they don’t,” she says.

Part of the challenge facing universities in formulating such policies is that student behavior so often seems contradictory. Participation in intercollegiate sports, for instance, seems to discourage smoking but has been associated with binge-drinking. “It’s important for colleges to take a multifaceted approach to these problems,” Emmons says. “They need to give students the confidence that if they can change one risk behavior, they can change another.”

The difficulty of making and enforcing such policies should not deter colleges from the effort, she remarks. “College is a transitional time in young people’s lives. It’s a time to try and figure out what your lifestyle is going to be like in the future. Colleges and universities have a responsibility to help shape those decisions in healthy directions.”

Emmons’ coauthors on the study were Henry Wechsler, PhD, and Melissa Abraham of the Harvard School of Public Health, and George Dowdall, PhD, of St. Joseph’s University in Philadelphia.

Articles in this issue

Preclinical Studies Using the Intratumoral Aromatase Model for Postmenopausal Breast Cancer
Phase II and III Clinical Trials of Toremifene for Metastatic Breast Cancer
Status of Antiestrogen Breast Cancer Prevention Trials
Antiestrogen Therapy: Uncertainties and Risk Assessment
Adjuvant Trials of Toremifene vs Tamoxifen: The European Experience
Pivotal Trials of Letrozole: A New Aromatase Inhibitor
Emerging Role of Aromatase Inhibitors in the Treatment of Breast Cancer
SGO Clinical Practice Guidelines: Introductory Remarks
Scientists Define New Role for Cell Signaling Pathway
Coalition Formed to Further Clinical Cancer Research
New Genetic Defect Signals Need for Aggressive Leukemia Treatment
Investigators Involved in Toremifene Studies Call It a Potentially Safer Antiestrogen
New Kind of Vaccine Aimed at Disseminated Melanoma
Steroid Improves Cancer-Fighting Ability of Vitamin D Analog
Study Links Smoking in College to Other Risky Student Behaviors
Recent Videos
1 expert is featured in this series.
2 experts are featured in this series.
2 experts are featured in this series.
5 experts are featured in this series
5 experts are featured in this series
2 experts in this video
“If you have a [patient in the] fourth or fifth line, [JNJ-5322] could be a valid drug of choice,” said Rakesh Popat, BSc, MBBS, MRCP, FRCPath, PhD.
2 experts in this video
Earlier treatment with daratumumab may be better tolerated for patients with pretreated MRD-negative multiple myeloma.
The trispecific antibody JNJ-5322 demonstrated superior efficacy vs approved agents in multiple myeloma in results shared at the 2025 EHA Congress.
Related Content
Advertisement

FDA Removes REMS, Lessens Requirements of Liso-cel/Ide-cel in Blood Cancers

FDA Removes REMS, Lessens Requirements of Liso-cel/Ide-cel in Blood Cancers

Tim Cortese
June 27th 2025
Article

The FDA had reduced driving and geographic restrictions to 2 weeks for patients with lymphomas and multiple myeloma receiving liso-cel and ide-cel.


Stephen Liu, MD, and Joshua Sabari, MD, discuss the most intriguing non–small cell lung cancer and small cell lung cancer breakthroughs from the meeting.

Practice-Changing Lung Cancer Data From the 2025 ASCO Annual Meeting

Stephen V. Liu, MD;Joshua K. Sabari, MD
June 23rd 2025
Podcast

Stephen Liu, MD, and Joshua Sabari, MD, discuss the most intriguing non–small cell lung cancer and small cell lung cancer breakthroughs from the meeting.


Tumor penetration of atigotatug in fuc-GM1-positive lung, liver, and bone lesions was observed in those with extensive-stage small cell lung cancer.

BMS-986279 Shows Feasibility as Non-Invasive fuc-GM1 Assessment in ES-SCLC

Roman Fabbricatore
June 27th 2025
Article

Tumor penetration of atigotatug in fuc-GM1-positive lung, liver, and bone lesions was observed in those with extensive-stage small cell lung cancer.


PODCAST: ASCO 2025 Debrief: Key Updates in Genitourinary Cancer Management

PODCAST: ASCO 2025 Debrief: Key Updates in Genitourinary Cancer Management

Manojkumar Bupathi, MD, MS;Benjamin Garmezy, MD
June 19th 2025
Podcast

Manojkumar Bupathi, MD, MS, and Benjamin Garmezy, MD, discuss abstracts from the 2025 ASCO Annual Meeting that may impact genitourinary cancer care.


Findings from the phase 2b ASCEND trial will be presented at the European Society for Medical Oncology Gastrointestinal Cancers Congress on July 2, 2025.

Certepetide Displays Positive Efficacy Trend in Metastatic PDAC

Roman Fabbricatore
June 27th 2025
Article

Findings from the phase 2b ASCEND trial will be presented at the European Society for Medical Oncology Gastrointestinal Cancers Congress on July 2, 2025.


Elraglusib plus gemcitabine and nab-paclitaxel demonstrated a median OS of 12.5 months vs 8.5 months with chemotherapy alone in patients with PDAC.

Elraglusib Plus Chemo Improves OS in Metastatic PDAC With Liver Metastases

Tim Cortese
June 27th 2025
Article

Elraglusib plus gemcitabine and nab-paclitaxel demonstrated a median OS of 12.5 months vs 8.5 months with chemotherapy alone in patients with PDAC.

Related Content
Advertisement

FDA Removes REMS, Lessens Requirements of Liso-cel/Ide-cel in Blood Cancers

FDA Removes REMS, Lessens Requirements of Liso-cel/Ide-cel in Blood Cancers

Tim Cortese
June 27th 2025
Article

The FDA had reduced driving and geographic restrictions to 2 weeks for patients with lymphomas and multiple myeloma receiving liso-cel and ide-cel.


Stephen Liu, MD, and Joshua Sabari, MD, discuss the most intriguing non–small cell lung cancer and small cell lung cancer breakthroughs from the meeting.

Practice-Changing Lung Cancer Data From the 2025 ASCO Annual Meeting

Stephen V. Liu, MD;Joshua K. Sabari, MD
June 23rd 2025
Podcast

Stephen Liu, MD, and Joshua Sabari, MD, discuss the most intriguing non–small cell lung cancer and small cell lung cancer breakthroughs from the meeting.


Tumor penetration of atigotatug in fuc-GM1-positive lung, liver, and bone lesions was observed in those with extensive-stage small cell lung cancer.

BMS-986279 Shows Feasibility as Non-Invasive fuc-GM1 Assessment in ES-SCLC

Roman Fabbricatore
June 27th 2025
Article

Tumor penetration of atigotatug in fuc-GM1-positive lung, liver, and bone lesions was observed in those with extensive-stage small cell lung cancer.


PODCAST: ASCO 2025 Debrief: Key Updates in Genitourinary Cancer Management

PODCAST: ASCO 2025 Debrief: Key Updates in Genitourinary Cancer Management

Manojkumar Bupathi, MD, MS;Benjamin Garmezy, MD
June 19th 2025
Podcast

Manojkumar Bupathi, MD, MS, and Benjamin Garmezy, MD, discuss abstracts from the 2025 ASCO Annual Meeting that may impact genitourinary cancer care.


Findings from the phase 2b ASCEND trial will be presented at the European Society for Medical Oncology Gastrointestinal Cancers Congress on July 2, 2025.

Certepetide Displays Positive Efficacy Trend in Metastatic PDAC

Roman Fabbricatore
June 27th 2025
Article

Findings from the phase 2b ASCEND trial will be presented at the European Society for Medical Oncology Gastrointestinal Cancers Congress on July 2, 2025.


Elraglusib plus gemcitabine and nab-paclitaxel demonstrated a median OS of 12.5 months vs 8.5 months with chemotherapy alone in patients with PDAC.

Elraglusib Plus Chemo Improves OS in Metastatic PDAC With Liver Metastases

Tim Cortese
June 27th 2025
Article

Elraglusib plus gemcitabine and nab-paclitaxel demonstrated a median OS of 12.5 months vs 8.5 months with chemotherapy alone in patients with PDAC.

Advertisement
About
Advertise
CureToday.com
OncLive.com
OncNursingNews.com
TargetedOnc.com
Editorial
Contact
Terms and Conditions
Privacy
Do Not Sell My Personal Information
Contact Info

2 Commerce Drive
Cranbury, NJ 08512

609-716-7777

© 2025 MJH Life Sciences

All rights reserved.